Exact Mass: 362.1913736
Exact Mass Matches: 362.1913736
Found 129 metabolites which its exact mass value is equals to given mass value 362.1913736,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
17,21-Epoxy-9-fluoro-11beta-hydroxyprogesterone
N-(4-Fluorophenyl)-4,5-dimethyl-6-[(1S)-1-methyl-3,4-dihydro-1H-isoquinolin-2-YL]pyrimidin-2-amine
C22H23FN4 (362.19066499999997)
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent
Benzetimide
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
Remifentanil Acid
C19H26N2O5 (362.18416260000004)
9R-(beta-D-glucopyranosyloxy)-cis-cascarillic acid|parisveroside A
Prolylleucine
C19H26N2O5 (362.18416260000004)
Prolylleucine is a dipeptide containing branched-chain amino acids. Prolylleucine can affect the circadian rhythms and behaviour of animals[1][2].
(4R,4R)-2,2-(PROPANE-2,2-DIYL)BIS(4-BENZYL-4,5-DIHYDROOXAZOLE)
solifenacin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
sodium n-tridecylbenzenesulfonate
C19H31NaO3S (362.18914960000006)
4,4-DIISOCYANATO-3,3,5,5-TETRAETHYLDIPHENYLMETHANE
Dexetimide
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease[1][2].
EPOXYPROPOXYPROPYL TERMINATED POLYDIMETHYLSILOXANE
4-(4-propylcyclohexyl)-4-(trifluoromethoxy)-1,1-biphenyl
[1-(2,3-Dihydro-benzo[1,4]dioxine-2-carbonyl)-piperidin-4-yl]-carbaMic acid tert-butyl ester
C19H26N2O5 (362.18416260000004)
2,8-Diazaspiro[5.5]undecane-1,7-dione, 2,8-bis(phenylmethyl)-
1-[4-[1-(3-methoxy-4-nitrophenyl)piperidin-4-yl]piperazin-1-yl]ethanone
C18H26N4O4 (362.19539560000004)
4-[3-Oxo-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-YL)-propenyl]-benzoic acid
Clometherone
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
(6S)-6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
(3r)-3-Hydroxy-2,2-Dimethyl-4-Oxo-4-({3-Oxo-3-[(2-Sulfanylethyl)amino]propyl}amino)butyl 2,2-Dimethylpropanoate
C16H30N2O5S (362.18753300000003)
(9S,12S)-9-(1-methylethyl)-7,10-dioxo-2-oxa-8,11-diazabicyclo[12.2.2]octadeca-1(16),14,17-triene-12-carboxylic acid
C19H26N2O5 (362.18416260000004)
benzetimide
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
5-(Phenylmethoxymethyl)-7-(1-piperidinylmethyl)-8-quinolinol
2,4-Dimethyl-5-furo[3,2-b]pyrrolecarboxylic acid [3-methyl-1-oxo-1-(2-oxolanylmethylamino)butan-2-yl] ester
C19H26N2O5 (362.18416260000004)
(4S)-4-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester
17,21-Epoxy-9-fluoro-11-hydroxypregn-4-ene-3,20-dione, (11beta)-
N(6)-L-homocysteinyl-N(2)-L-valyl-L-lysine
C15H30N4O4S (362.19876600000003)
1-[(4-Chlorophenyl)-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-4-methylpiperazine
methyl (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-(oxan-4-ylmethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylate
C19H26N2O5 (362.18416260000004)
N-[2-[(2R,5S,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2R,5R,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2S,5S,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]propanamide
C19H26N2O5 (362.18416260000004)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]propanamide
C19H26N2O5 (362.18416260000004)
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]propanamide
C19H26N2O5 (362.18416260000004)
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-(4-oxanylmethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
C19H26N2O5 (362.18416260000004)
1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone
(6S,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
N-[2-[(2S,5R,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2R,5R,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2R,5S,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2S,5S,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[2-[(2S,5R,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide
C18H26N4O4 (362.19539560000004)
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]propanamide
C19H26N2O5 (362.18416260000004)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]propanamide
C19H26N2O5 (362.18416260000004)
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]propanamide
C19H26N2O5 (362.18416260000004)
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]propanamide
C19H26N2O5 (362.18416260000004)
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]propanamide
C19H26N2O5 (362.18416260000004)
1-[(3aS,4R,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone
1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone
1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone
(6R,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
revaprazan
C22H23FN4 (362.19066499999997)
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent
Levetimide
Levetimide is a potent and stereoselective inhibitor of [3H](+)pentazocine binding, with a Ki of 2.2 nM[1].
2-[({6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl}methyl)amino]-3-(c-hydroxycarbonimidoyl)propanoic acid
C19H26N2O5 (362.18416260000004)
(2E,6E)- 3,7,11-trimethyl-9-(phenylsulfonyl)-2,6,10-dodecatrien-1-ol
{"Ingredient_id": "HBIN005569","Ingredient_name": "(2E,6E)- 3,7,11-trimethyl-9-(phenylsulfonyl)-2,6,10-dodecatrien-1-ol","Alias": "NA","Ingredient_formula": "C21H30O3S","Ingredient_Smile": "CC(=CC(CC(=CCCC(=CCO)C)C)S(=O)(=O)C1=CC=CC=C1)C","Ingredient_weight": "362.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "41632","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "5368759","DrugBank_id": "NA"}
5-(1-benzofuran-2-yl)-2-[(1s,2s,5s)-5-methyl-2-(prop-1-en-2-yl)cyclohexyl]benzene-1,3-diol
23-oxotetracosa-3,5,7,9,11,13,15,17,19,21-decaenoic acid
(2r,21z)-2-hydroxytetracos-21-en-3,12,14,16,23-pentaynoic acid
2-({[(3as)-6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl]methyl}amino)-3-(c-hydroxycarbonimidoyl)propanoic acid
C19H26N2O5 (362.18416260000004)
1-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-6-methoxyphenazine
(2s)-2-({[(3r,3as,6ar,9ar,9bs)-6,9-dimethylidene-2-oxo-octahydro-3h-azuleno[4,5-b]furan-3-yl]methyl}amino)-3-(c-hydroxycarbonimidoyl)propanoic acid
C19H26N2O5 (362.18416260000004)